APUS vs BROS · $2.4M cap vs P/E 105, rev $1.02B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Dutch Bros Inc (BROS) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Dutch Bros Inc (BROS) is a restaurants company listed on NYSE.
APUS does not have a complete income-statement cache yet.
Latest reported BROS revenue for 2026-06-30 was $1.02B. Net income was $53.5M. BROS currently screens at market cap $11.74B and trailing P/E 105.0.
APUS currently screens at market cap $2.4M. BROS currently screens at market cap $11.74B and trailing P/E 105.0.
Not investment advice. Open the APUS and BROS stock pages for the full models.
Not investment advice.